Profil bibliographique

Yoonjin Cho

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

7Publications signalées

16Citations signalées

0Affiliations récentes

Les domaines associés

Lysosomal Storage Disorders ResearchParasites and Host InteractionsResearch on Leishmaniasis StudiesPlanarian Biology and ElectrostimulationNeurology and Historical Studies

Les publications récentes

2025 article OpenAlex

Campsiite® phase I/II/III: an interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

Paul Harmatz, Can H. Ficicioglu, Roberto Giugliani, Deepa Rajan et autres

0 citations Molecular Genetics and Metabolism

2024 article OpenAlex

CAMPSIITE™ Phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

Laura Jean Pisani, Can H. Ficicioglu, Paul Harmatz, Roberto Giugliani et autres

us, br (code pays fourni par la source)

1 citation Molecular Genetics and Metabolism

2024 article OpenAlex

CAMPSIITE™ phase I/II/III: An interim clinical study update of RGX-121, an investigational gene therapy for the treatment of neuronopathic mucopolysaccharidosis type II (MPS II)

Paul Harmatz, Can H. Ficicioglu, Roberto Giugliani, Deepa Soundara Rajan et autres

1 citation Molecular Genetics and Metabolism

2022 article OpenAlex

NATURAL HISTORY OF NEURODEVELOPMENT IN NEURONOPATHIC MUCOPOLYSACCHARIDOSIS TYPE II (MPS II): MULLEN SCALES OF EARLY LEARNING (MSEL) COGNITIVE, MOTOR AND LANGUAGE DEVELOPMENTAL TRAJECTORIES

Dawn Phillips, Yoonjin Cho, Caroline M. Mulatya, Marie-Laure Névoret et autres

us (code pays fourni par la source)

1 citation Molecular Genetics and Metabolism

2022 conference-abstract OpenAlex

RGX-111 GENE THERAPY FOR THE TREATMENT OF SEVERE MUCOPOLYSACCHARIDOSIS TYPE I (MPS I): INTERIM ANALYSIS OF DATA FROM A PHASE 1/2 STUDY

Raymond Wang, Can H. Ficicioglu, Roberto Giugliani, Marie-Laure Névoret et autres

us, br (code pays fourni par la source)

1 citation Molecular Genetics and Metabolism

2022 conference-abstract OpenAlex

RGX-121 GENE THERAPY FOR THE TREATMENT OF SEVERE MUCOPOLYSACCHARIDOSIS TYPE II (MPS II): INTERIM ANALYSIS OF DATA FROM A PHASE 1/2 STUDY

Can H. Ficicioglu, Maria Luisa Escolar, Roberto Giugliani, Paul Harmatz et autres

us, br (code pays fourni par la source)

1 citation Molecular Genetics and Metabolism

2021 conference-abstract OpenAlex

RGX-121 gene therapy for severe Mucopolysaccharidosis Type II (MPS II): Interim neurodevelopmental outcomes and biomarker results (4164)

Paul Harmatz, Maria Luisa Escolar, Can H. Ficicioglu, Roberto Giugliani et autres

To evaluate the safety and efficacy of CNS-administered gene therapy for severe MPS II

us, br (code pays fourni par la source)

11 citations Neurology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.